Sentence examples for lack of psa from inspiring English sources

Given that the lack of PSA does not affect overall synapse numbers [40], the role of PC in this process may be independent of PSA.

While these cells are described as androgen-independent PCa cells, they are generally considered as non-prostate-like cancer cells mainly due the deficiency of androgen receptors and thereby lack of PSA expression.

In addition, since the GRS SNPs used in this study were identified based on genetic studies of psoriasis and not PsA per se, lack of association with PsA may simply indicate that the present SNPs do not account for genetic susceptibility to the arthritic component.

Despite the obvious lack of specificity for PsA, PGRN Abs are of particular interest because they had a neutralizing effect on PGRN plasma levels detected by ELISA and Western blot analysis [ 8].

However, the large majority of PsA patients lack HLA-B*27, and the development of PsA in association with other HLA alleles is not accounted for by this mechanism.

The reasons for this uncertainty include disparity in the subgroups identified in the original description [ 1], lack of a validated case definition of PsA, possible inclusion of patients with enthesitis but without clear arthritis, the elusive link between skin and joint diseases, and similarities with rheumatoid arthritis (RA).

The lack of information describing the indirect costs of PsA does not reflect its impact on society.

The lack of discrimination between RA and PsA with a 0.2-T MRI device could be overcome with other MRI protocols, such as different pulse sequences, field strengths, or magnet types.

Because this IL-22 expression was found even in the absence of synovitis in the mouse model [ 43], and since we observed a striking and specific lack of IL-22 staining in PsA ST, it will be of interest in future studies to determine whether IL-22 is also expressed in entheseal biopsies from patients with PsA.

ACR50 and mPsARC responses were achieved by five and seven, respectively, of 13 patients with PsA with lack of response to prior TNF-antagonist treatment; by 10 and 17 of 27 patients with loss of response; and by five and seven of eight patients who were intolerant of prior anti-TNF therapy (observed data).

Patients with PsA who had lack of response to prior TNF-antagonist therapy experienced somewhat less clinical improvement with adalimumab compared with patients with loss of response or intolerance to their prior TNF-antagonist treatment.